west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "甲钴胺" 4 results
  • 地奥司明联合甲钴胺治疗腰椎间盘突出症的临床观察

    目的 探讨地奥司明片联合甲钴胺对腰椎间盘突出症药物治疗的临床疗效。 方法 选择2011年12月-2012年10月在门诊行非手术治疗的腰椎间盘突出症患者80例,患者按完全随机化原则分为两组,每组40例,治疗组使用地奥司明片+甲钴胺;对照组单纯使用甲钴胺,观察两组疗效,并给予分析总结。 结果 两组患者均经5~20 d随访,治疗组明显好转15例,好转18例,总有效率82.5%;对照组明显好转8例,好转15例,有效率57.25%,两组比较差异有统计学意义(P<0.05)。 结论 联合用药治疗腰椎间盘突出症可明显缓解急性期腰椎间盘突出症症状。

    Release date:2016-09-07 02:37 Export PDF Favorites Scan
  • 甲钴胺联合黛力新治疗丘脑痛的临床观察

    【摘要】 目的 观察甲钴胺(商品名:弥可保)联合氟哌噻吨+美利曲辛(商品名:黛力新)治疗丘脑痛的临床疗效。 方法 将58例丘脑痛患者随机分为两组,治疗组采用甲钴胺联合黛力新治疗(n=30);对照组单独应用黛力新治疗(n=28)。以视觉模拟评分法(VAS) 和临床治愈率作为疗效评估指标。结果 甲钴胺联合黛力新治疗组VAS 评分治疗前后分别为7.39±1.32,4.28±0.79,差异有统计学意义(t=3.97,Plt;0.001);黛力新组治疗前后分别为7.21±1.23,6.78±1.31,差异无统计学意义(t=0.48,Pgt;0.05)。联合治疗组临床治愈19例,总有效率63.3%;对照组临床治愈8 例,总有效率28.6%,两组比较差异有统计学意义(χ2=20.92,Plt;0.01)。结论 甲钴胺、黛力新联用治疗丘脑痛的疗效优于黛力新单药治疗。

    Release date:2016-09-08 09:45 Export PDF Favorites Scan
  • 银杏叶注射液联合甲钴胺治疗糖尿病周围神经病变

    目的 观察银杏叶注射液联合甲钴铵治疗糖尿病周围神经病变(DPN)临床疗效。 方法 选择2007年9月-2009年10月收治的DPN患者75例,随机分为观察组和对照组,两组均给予甲钴胺口服,观察组在此治疗基础上加用银杏叶注射液。 结果 治疗1个疗程后,观察组疗效优于对照组,两组比较总有效率有统计学意义(Plt;0.05);观察组治疗后与治疗前比较,有统计学意义(Plt;0.05),对照组无差异 (Pgt;0.05)。两组治疗后神经传导速度比较,观察组优于对照组,有统计学意义(Plt;0.05)。 结论 在有效控制血糖基础上,银杏叶注射液联合甲钴胺治疗糖尿病周围神经病变是一种有效的方法,建议临床推广。

    Release date:2016-09-08 09:49 Export PDF Favorites Scan
  • Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy

    ObjectiveTo study the effect of combined treatment using pancreatic kinionogenase enteric-coated tab and mecobalamin injection on diabetic peripheral neuropathy (DPN) patients. MethodsWe collected 84 subjects with DPN who received treatment from January 2012 to December 2012 in our hospital, and we randomly divided them into treatment group (42 subjects, using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection) and control group (42 subjects, using mecobalamine only). Subjects in the treatment group were given oral pancreatic kininogenase at 120 unit/times and 3 times/day, and methylcobalamin intravenous injection at 1 mg/day for 14 days. Subjects in the control group were only given methylcobalamin intravenous injection at 1 mg/day for 14 days. ResultsIn the treatment group, 22 subjects showed excellent, 19 subjects effective and 1 subject ineffective outcome. In the control group, 8 subjects showed excellent, 22 effective and 12 ineffective outcome. The difference between the two groups is statistically significant (P<0.01). Compared with no treatment, the nerve conduction velocity in both the two groups has been improved. The improvement in the treatment group is significantly better than that of the control group (P<0.01), and all of them had no obvious adverse reaction during the treatment. ConclusionThe combined treatment using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection on DPN is better than using methylcobalamin only.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content